NUVL Strangle Strategy
NUVL (Nuvalent, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties.
NUVL (Nuvalent, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $9.09B, a beta of 1.15 versus the broader market, a 52-week range of 71.13-123.69, average daily share volume of 2.1M, a public-listing history dating back to 2021, approximately 162 full-time employees. These structural characteristics shape how NUVL stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.15 places NUVL roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on NUVL?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current NUVL snapshot
As of June 30, 2026, spot at $123.50, ATM IV 2.10%, IV rank 0.17%, expected move 0.60%. The strangle on NUVL below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this strangle structure on NUVL specifically: NUVL IV at 2.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a NUVL strangle, with a market-implied 1-standard-deviation move of approximately 0.60% (roughly $0.74 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NUVL expiries trade a higher absolute premium for lower per-day decay. Position sizing on NUVL should anchor to the underlying notional of $123.50 per share and to the trader's directional view on NUVL stock.
NUVL strangle setup
The NUVL strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NUVL near $123.50, the first option leg uses a $129.68 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NUVL chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NUVL shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $129.68 | N/A |
| Buy 1 | Put | $117.32 | N/A |
NUVL strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
NUVL strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on NUVL. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on NUVL
Strangles on NUVL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NUVL chain.
NUVL thesis for this strangle
The market-implied 1-standard-deviation range for NUVL extends from approximately $122.76 on the downside to $124.24 on the upside. A NUVL long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NUVL IV rank near 0.17% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NUVL at 2.10%. As a Healthcare name, NUVL options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NUVL-specific events.
NUVL strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NUVL positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NUVL alongside the broader basket even when NUVL-specific fundamentals are unchanged. Always rebuild the position from current NUVL chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on NUVL?
- A strangle on NUVL is the strangle strategy applied to NUVL (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NUVL stock trading near $123.50, the strikes shown on this page are snapped to the nearest listed NUVL chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are NUVL strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NUVL strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 2.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NUVL strangle?
- The breakeven for the NUVL strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current NUVL market-implied 1-standard-deviation expected move is approximately 0.60%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on NUVL?
- Strangles on NUVL are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NUVL chain.
- How does current NUVL implied volatility affect this strangle?
- NUVL ATM IV is at 2.10% with IV rank near 0.17%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.